US biotech Amgen (Nasdaq: AMGN) has seen its quarterly revenues rise by 5% to $6.5 billion in comparison to the second quarter of 2020, a jump attributed to higher unit demand though partially offset by lower net selling prices.
Second-quarter 2021 adjusted earnings, helped by share buybacks, increased 4% from a year ago to $4.38 per share, beating the $4.10 forecast by Wall Street analysts, as calculated by Refinitiv.
On a generally accepted accounting principles (GAAP) basis, Amgen now expects earnings per share in the range of $8.84 to $9.90 for 2021 as a whole, where previously the company had predicted somewhere from $9.11 to $10.71.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze